INTRODUCTION {#s1}
============

Central poststroke pain (CPSP) is characterized by pain and sensory abnormalities in the body (when other causes of obvious nociceptive, psychogenic, or peripheral pain have been excluded) after cerebrovascular lesion of the somatosensory system[@r1], [@r2]^)^. The prevalence of CPSP has been reported to be 7.3%[@r2], [@r3]^)^. By a year after stroke onset, quality of life (QoL) decreases 40% compared with before a stroke[@r4]^)^. As pain is known to affect recreational activities, vocational status, and quality of sleep, it can have a major role on QoL, mood, and rehabilitation outcome[@r5],[@r6],[@r7]^)^. For many of patients with CSPS, the pain is severe and accompanied by reduced physical functioning, eventually lowering the QoL[@r8], [@r9]^)^. Further, pain and psychological disorders are closely related, affecting physical and psychosocial functioning[@r10], [@r11]^)^. Likewise, CPSP has an important effect on QoL, and a strong relationship has been observed between pain and depression[@r5]^)^.

Although CPSP can be expected to have a negative impact on QoL and mood in patients with stroke, to the best of our knowledge, no controlled study has been performed in this regard. Accordingly, the aim of this study was to assess the effects of CPSP on QoL and mood in patients with stroke and to determine the characteristics of CPSP. It was our hope that this study would encourage clinicians to may more attention to CSPS in patient with stroke.

SUBJECTS AND METHODS {#s2}
====================

Twenty-four patients with CPSP (a mean age of 60.6±8.5 years; 14 males, 10 females; Group I) and 24 similar age-and gender-matched patients with stroke without CPSP (Group II) were enrolled. All patients who underwent inpatient rehabilitation treatment at Ankara Physical Medicine and Rehabilitation Education and Research Center were examined between January 2013 and February 2014. The patients included in the study were able to speak and understand the tests, and had stroke with a duration of at least one month. Patients were excluded from the study if they were not unconscious or had nociceptive or neuropathic pain due to other causes (i.e., complex regional pain syndrome, shoulder problems, brachial plexus injuries). All patients signed an informed consent form, and the study protocol was approved by the local ethical committee.

Demographic characteristics (age, gender, marital status, educational level); duration, type, side of stroke; dominant hemisphere; and medical history were recorded. Lesion localizations were detected with magnetic resonance imaging. Examination of superficial sensation and proprioception was performed in all patients. Differences in sensory function response to application of cotton wool (light touch), a cold metal object (cold sensation), and a size 6.65 (sharpness) Semmes Weinstein filament were recorded. Proprioception was tested on thumbs and big toes. The tactile detection threshold was determined using Semmes Weinstein filaments (Touch-Test Hand Kit, North Coast Medical, Inc., USA)[@r6]^)^. Spasticity was assessed using the Modifiye Aschworth scale[@r12]^)^.

The patients were diagnosed with CPSP based on the diagnostic criteria of Klit et al[@r1]^)^. Duration, localization, characteristics, and rhythm of pain and the relationship between activity and treatment methods were recorded in patients with CPSP. Patients were asked to rate their average pain intensity during the past week on a Visual Analogue Scale (VAS), with 0 = "no pain" and 10 = "pain as bad as could be"[@r13]^)^. The Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) scale was used to discriminate between neuropathic and non-neuropathic pain[@r13]^)^. Scores of 12 or higher (out of a total of 24) were considered to indicate neuropathic pain. Pain type was classified into four categories according to location, description, and apparent origin as described elsewhere. CPSP is a neuropathic pain resulting from dysfunction of the central nervous system. It is characterized by pain and sensory abnormalities in the body parts corresponding to the brain territory injured by the cerebrovascular lesion. Pharmacologic agents used for neuropathic pain in CPSP. Adaptation of the LANSS scale to the Turkish patient population was carried out by Yücel et al[@r14]^)^. The VAS and LANSS scales were used only in Group I.

Functional outcomes, QoL, and depressive symptoms were assessed using the Turkish versions of the Functional Independence Measurement (FIM), 36-Item Short-Form Health Survey quality of life scale (SF-36 QoLS), and Beck Depression Inventory (BDI), respectively[@r15],[@r16],[@r17]^)^. FIM consist 6 subtests (self-care, sphincter control, transfer, locomotion, communication, and social cognitive ability) with a maximum total score of 126. The SF-36 QoLS measures 8 parameters as physical function, physical role limitations, pain, general health, energy/vitality, social function, mental status role, and mental health.[@r18]^)^ The subscales evaluate health with scores between 0 and 100 (0 = "worst health status" and 100 = "good health status"). The scores of two components, namely the physical and mental scores, were evaluated. BDI is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression. Higher total scores indicate more severe depressive symptoms[@r19]^)^.

SPSS Statistics 16.0 (SPSS, Chicago, IL, USA) was used for statistical analyses. Descriptive statistics were applied in the analyses. The chi-square test was used to compare the categorical data of both groups. The Mann-Whitney test was applied to compare the continuous variables between two groups. Pearson correlation analysis and linear regression analysis were performed to identify the relationship between physical and mental scores of the SF-36 QoLS and LANSS score. The level of statistical significance was set at p\<0.05.

RESULTS {#s3}
=======

Characteristics of the groups are presented in [Table 1](#tbl_001){ref-type="table"}Table 1.Characteristics of groupsGroup I\
n=24Group II\
n=24GenderFemale/Male15/911/13Marital statusMarried/Widowed20/422/2Educational LevelIlliterate/Primary school/ High school4/12/89/10/5Duration of stroke (months)6 (18/2)4 (6/3)Type of strokeIschemic/Hemoragic20/418/6Side of strokeRight/Left16/815/9Dominant hemisphereRight/Left22/221/3Number of comorbidities1 (3/1)1 (2/0)Localization of lesionThalamus/Extrathalamus/Brain stem\*\*14/7/31/22/1Sensorial deficitPresent/Absent11/1319/5SpasticityPresent/Absent13/1116/8CPSP: central poststroke pain. Data are given as mean±standard deviation, ratio and median (max/min). n: number. ^\*\*^p \< 0.01. There were no significant differences between the groups except lesion localization. Pain-related features of the patients with stoke and CPSP are presented in [Table 2](#tbl_002){ref-type="table"}Table 2.Pain-related features in patients with central post-stroke pain (n=24)mean±SD, n (%), median (max/min)Duration of pain (months)2.3±0.9 (1--4)Localization of painExtremity/Face and extremity/Body and extremity/Face, body and extremity9 (37.5) /5 (20.8) /1 (4.2)/ 9 (37.5)Characteristics of painBurning1 (4.2)Pricking1 (4.2)Burning and pricking14 (58.3)Burning and lacerating1 (4.2)Burning, pricking and throbbing2 (8.3)Burning, aching and throbbing3 (12.5)Aching and lacerating2 (8.3)Relationship with activityDecreasing/Stable10 (41.6)/ 8 (58.3)Rhythm of painMorning/Evening /Night6 (25)/ 2 (8.3)/ 16 (66.6)TreatmentOnly anticonvulsant13 (54.6)Anticonvulsant plus NSAID5 (30.0)Anticonvulsant plus opioids4 (16.8)Anticonvulsant plus NSAID plus opioids2 (8.4)VAS scores7.5±1.0LANSS scores9.5 (18/0)CPSP: central poststroke pain, NSAID: non-steroidal anti-inflammatory drugs, VAS: Visual Analog Scale, LANSS: Leeds Assessment of Neuropathic Symptoms and Signs, n: number. Data are given as mean ± standard deviation, ratio and median (max/min). Accordingly, the most common localization of pain was on one side of the body (including face, upper and lower extremities). The most common characteristics of pain were burning, pricking, throbbing, diminishing with activity, and increasing at night. Most patients were taking analgesics and⁄or an anticonvulsant for treatment. Hyperalgesia and allodinia were observed in 87.5% of these patients. Sensorial deficit was observed 19 of 24 patients with CPSP (79%). In our sample of patients, 45.8% presented with light touch, 8.3% with light touch with proprioception, and 12.5% with light touch with temperature sensation deficits.

Comparisons of clinical variables in both groups are presented in [Table 3](#tbl_003){ref-type="table"}Table 3.Comparison of clinical variables in between groupsGroup IGroup IIFIM scaleMotor FIM59 (80/41)61.5 (89/26)Cognitive FIM33 (35/21)35 (35/21)Total FIM89.5 (115/76)95.5 (119/61)SF-36QoLSPhysical function15.2 (19.4/15.2)15.2 (27.8/15.2)Physical role limitations\*28 (56.2/28)28 (28/28)Pain33.2 (46.5/19.9)49.4 (62.7/11.6)General health28.9 (41.5/26.5)28.9 (54.6/24.2)Vitality37.2 (46.7/25.4)38.4 (53.8/28.4)Social function30 (46.3/13.7)24.6 (46.3/19.1)Mental status role23.7 (55.3/23.7)23.7 (55.3/23.7)Mental health28.9 (50.4/16.4)32.2 (50.4/14.1)Physical score\*\*25 (32.7/17.5)28.8 (42.1/24.3)Mental score30.7 (51.4/21.6)33.2 (59.7/17.9)BDI scale18 (32/1)14 (25/9)CPSP: central poststroke pain, FIM: Functional Independence Measurement, SF-36 QoLS: Short-Form 36 Quality of Life Scale, BDI: Beck Depression Inventory. Data are given as median (max/min). ^\*^p\<0.05, ^\*\*^p \< 0.01. There were no significant differences in FIM (motor, cognitive, total) and BDI scores. Some of the SF-36 domains (physical role limitations, pain, and physical scores) in Group II were significantly higher than in Group I (p\<0.005). Moderate negative correlation was found between the LANSS scores and physical score (p=0.0001, r=−0.619). Linear regretion revealed that a unit increase in LANNS score led to a 0.679 decrease in physical score \[r=0.639 f(1,61)=42.15 beta=−0.679 \] (p=0.0001) and a 0.387 decrease in mental score \[r=0.214 f(1,61)=2.91 beta=−0.387\] (p=0.093).

DISCUSSION {#s4}
==========

Central poststroke pain may significantly affect functionality and negatively influence physical activity of patients with stroke but very few data on this topic are available[@r5], [@r8], [@r20]^)^. Most commonly, CPSP develops within 3 to 6 months of stroke, although it may occur within a month after stroke[@r16]^)^. In our patients, pain onset occurred between 1 and 4 months after stroke. The presentation of CPSP is variable. Adjectives such as lacerating, aching, burning, freezing, and squeezing are commonly used by patients[@r21]^)^, as observed in our patients. Regarding the location of pain, hemisyndrome or lower limb involvement is frequently noted[@r1]^)^, which is in agreement with the present study. Additionally, the severity of pain decreased with activity and increased at night in our patients. Some studies showed that the intensity of spontaneous pain fluctuated frequently and could be increased by internal or external stimuli (such as stress or cold) and alleviated by rest or distraction[@r22]^)^.

Higher spasticity and sensory deficits are usually related to more severe neuropathic pain[@r5]^)^. The association between spasticity and neuropathic pain suggests that the role of spasticity in the pathogenesis of poststroke pain should be reevaluated and that the possibility of developing abnormal brain plasticity should be considered. In contrast we found that CPSP was not related to sensory impairment and spasticity.

Central poststroke pain was attributed to a thalamic lesion in the past, but it is known to also be associated with extrathalamic lesions[@r3], [@r21]^)^. Localization in the thalamus was more common in our patients with CPSP. In some studies, higher pain intensities have been reported when the lesions were located in the brainstem or thalamus than in other areas; however, in another study, the symptoms and severity of CPSP in thalamic versus extrathalamic stroke did not differ[@r21], [@r23]^)^. Further studies with a large number of stroke patients with CPSP are needed to clarify this topic.

Central poststroke pain is challenging to treat, and often involves a trial-and-error process with multiple different therapies[@r21]^)^. The majority of our patients were treated with analgesic/anti-inflammatory drugs and an anticonvulsant, in agreement with study by Zorowitz et al. In their study, the most frequently prescribed pain medications for CPSP were analgesics, acetaminophen and tramadol, followed by an anticonvulsant[@r24]^)^.

In our study, no differences between the groups in FIM indicated that CPSP did not affect the functional outcomes. One previous study stated that CPSP was not a disturbing symptom for patients and did not limit daily activities[@r25]^)^. This was the expected result; CPSP affected the physical function, pain, and physical score components of the SF-36 QoLS poorly, but the other components of the SF-36 QoLS were not affected in our patients. Previous studies showed that CPSP affected not only physical functions but also mental functions poorly[@r26],[@r27],[@r28]^)^. We thought that this difference was due to the protocol of our study which was a controlled study. Additionally, CPSP did not affect the depression and mental scores of the SF-36 QoLS in our study and these results were in agreement with previous studies. In contrast, Appelros detected a strong relationship between poststroke pain and depression[@r29]^)^. Widar et al. stated that poststroke pain was associated with sleep disturbances, fatigue, lack of fitness, mood lability and stress[@r30]^)^. Further controlled studies with a large number of stroke patients with CPSP are needed to clarify the effect of CPSP on the state of mind related to QoL.

In conclusion, to best of our knowledge, this is the first controlled study indicatin that CPSP has a negative impact on the physical subscale score of the SF-36 QoLS in patients with stroke. We propose that CPSP should be treated in a multidisciplinary setting to improve QoL.
